newscontact us

ThermoGenesis Reports First Quarter Fiscal 2014 Results

Company Achieves Significant Clinical and Operating Milestones

RANCHO CORDOVA, Calif., Nov. 14, 2013 (GLOBE NEWSWIRE) — ThermoGenesis Corp. (Nasdaq:KOOL) (“ThermoGenesis”), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the first quarter of fiscal 2014.

For the quarter ended September 30, 2013, revenues were $3.6 million, compared to $4.1 million for the same period in 2012. The decrease in year-over-year revenues of $478,000 was primarily attributable to an anticipated temporary decrease in AXP disposable revenues due to the termination of the GE distribution agreement and the related wind-down of their inventory. This decrease was partially offset by increases in AXP sales in the Asian market.

111413 Earnings Call Press Release FY14Q1 Final